A Case of Gastroesophageal Cancer after Laparoscopic Sleeve Gastrectomy by Aljarboo, Ahmad et al.
JGS
OPEN ACCESS
www.journalofgastricsurgery.com
CASE REPORT
A Case of Gastroesophageal Cancer after 
Laparoscopic Sleeve Gastrectomy
Ahmad A. Aljarboo1*, Faisal Alghamdi1, Abdullah Alzahrani1, Bandar Ali1
1Department of General Surgery, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
To Cite
Aljarboo A. A, Alghamdi F, Alzahrani A, Ali 
B. A Case of Gastroesophageal Cancer after 
Laparoscopic Sleeve Gastrectomy. J Gastric 
Surg 2020; 2(4).
Publication history
Received: September 29, 2020
Accepted: October 01, 2020
Article in press: October 02, 2020
Published online: October 05, 2020
*Correspondence to
Ahmad A. Aljarboo, MD 
Department of General Surgery 
Prince Sultan Military Medical City 
Makkah Al Mukarramah Rd, As Sulimaniyah 
12233, Riyadh, Saudi Arabia.
ahmadaljarboo@gmail.com 
ABSTRACT
Gastric cancer has been reported in relatively few cases after sleeve gastrectomy, which 
has become a common bariatric procedure. In this paper, we present a 58-year-old woman 
diagnosed with gastric cancer by esophagogastroduodenoscopy (EGD) 4 years after 
sleeve gastrectomy. For that, she underwent distal esophagectomy and total gastrectomy 
with Roux-en-Y esophagojejunostomy. Preoperative endoscopy is recommended before 
planning surgery in patients with gastroesophageal reflux symptoms. In addition, annual 
EGD should be considered after sleeve gastrectomy in patients with risk factors for 
gastric cancer.
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Background
Obesity is a major cause of morbidity and mortality 
worldwide, including its reported risk for causing 
esophageal and gastric cancer.[1, 2] Bariatric surgery, in 
general, offers an efficient solution to reducing weight, 
with non-surgical therapy being ineffective in a large 
number of cases. Sleeve gastrectomy is a widely used 
procedure, with possible reported complications such 
as leakage, strictures, bleeding, nutrient deficiency, and 
gastroesophageal reflux disease (GERD).[3] However, 
relatively few cases of gastric adenocarcinoma post-
sleeve gastrectomy were reported (to the best of our 
knowledge, 7 cases have been reported in English 
literature).
Case Report
The patient is a 58-year-old woman known to have 
hypertension, hypothyroidism, bronchial asthma, 
rheumatoid arthritis, and a history of GERD. She 
denied having a family history of gastrointestinal (GI) 
malignancy, and she has no history of smoking. She 
underwent laparoscopic sleeve gastrectomy in April 2016 
in another institution; at that time, she had a body mass 
index (BMI) of 52 kg/m2. In October 2017, the patient 
presented with failure to reduce her weight beyond a 
BMI of 42 kg/m2. An esophagogastroduodenoscopy 
(EGD) was performed due to symptoms of GERD and 
iron deficiency anemia and showed a moderate hiatal 
hernia with mild reflux esophagitis (grade A, Los Angeles 
classification). In addition, a biopsy was taken from the 
patient’s stomach, which showed chronic gastritis with 
the presence of Helicobacter pylori (H. Pylori) and no 
dysplasia or malignancy. The patient received treatment 
of H. Pylori and revisional surgery and hiatal hernia 
repair was planned to control her symptoms and her 
weight, but the procedure was not completed due to a 
long waiting list.
In January 2020, the patient underwent EGD due to 
progressive mild dysphagia to solid and liquid food over 
4 months, which showed an ulcerated polypoid mass at 
the gastroesophageal junction 35cm from the incisors, 
with the rest of stomach and duodenum showing normal 
mucosa (Figure 1). 
Figure 1: EGD showing polypoid mass on the gastroesopha-
geal junction (A) with ulceration shown along the gastroe-
sophageal junction (B).
A biopsy from the mass showed invasive moderately 
differentiated adenocarcinoma. The tumor markers 
were alpha-fetoprotein (AFP) <0.75 ng/mL, 
carcinoembryonic antigen (CEA) 3.5 ng/mL, 
carbohydrate antigen (CA-125) 13 U/mL, and carcinoid 
antigen (CA19-9) 57 U/mL. Staging computed 
tomography for the chest, abdomen, and pelvis (CT 
CAP) and positron emission tomography (PET-CT) 
showed hypermetabolic polypoid circumferential 
thickening involving the known herniated stomach with 
extension into the gastroesophageal junction associated 
with multiple gastrohepatic and left para-aortic 
lymphadenopathy (Figure 2).
Figure 2: (A) Axial view of CT chest with asterisk showing 
the cancer, (B) PET-CT with asterisk showing the cancer 
with hypermetabolic activity, (C) Coronal view of CT chest 
with asterisk showing the cancer with hiatal hernia noted.).
The patient was taken for diagnostic laparoscopy with 
peritoneal lavage for staging, where the tumor was seen 
at the cardia of the stomach up to the gastroesophageal 
junction, with great omentum seeding visualized. A 
biopsy was taken, and the solid organs were intact with 
no ascites. The biopsy from the omental seeding showed 
no evidence of metastatic carcinoma. The cytology report 
from the peritoneal fluid showed scattered atypical 
cells and mucin, with degenerated mesothelial cells 
in a background of lymphocytes and red blood cells, 
which are signs of malignancy. The case was discussed 
during the multidisciplinary tumor board meeting, 
which planned for neoadjuvant chemotherapy. The 
patient started in 4 cycles (5-Fluorouracil, Leucovorin, 
Oxaliplatin, and Docetaxel) for approximately 8 weeks. 
The follow up after chemotherapy with PET-CT showed 
almost complete resolution of the mass with only 
mild gastroesophageal thickening showing minimal 
metabolic activity (Figure 3). 
Figure 3: PET-CT, with asterisk showing almost complete 
resolution of the previously seen hypermetabolic gastroe-
sophageal junction mass.
In June 2020, the patient underwent surgery, distal 
esophagectomy, and total gastrectomy with Roux-en-Y 
esophagojejunostomy and saw an uneventful recovery. 
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Final pathological staging (pT2 N1M0) showed no 
lymphovascular or perineural invasion, and all surgical 
margins were free.[4] The patient was discharged on day 
11 post operation, after ensuring no leaks via an upper 
GI study.
Discussion
Gastric cancer is uncommon in Saudi Arabia.[5] Its 
incidence is decreasing worldwide due to the early 
detection and eradication of H.pylori infection, which 
is one of the most common independent risk factors.
[6] In addition, there are multiple environmental 
and genetic factors. Hiatal hernia and GERD are 
considered significant risk factors for esophageal and 
gastric cardia adenocarcinoma, with an increase in 
fold when combined.[7] Nowadays, preoperative EGD 
is performed routinely before planning any bariatric 
surgery in our institution, although it is still debated 
and selective in many studies.[8] It is important to check 
for signs of gastritis, H.pylori, and dysplasia or masses 
before surgery, especially before gastric bypass since 
the patient’s anatomy will be disturbed. Interestingly, 
there are reported cases of gastric cancer diagnosed 
after sleeve gastrectomy. Two cases have been reported 
to have GERD, which was the only underlying risk 
factor.[9, 10] Another two patients were known to have 
hiatal hernia, which was repaired during the sleeve 
gastrectomy.[11, 12] However, there was no H.pylori 
detected in those cases. The resected stomach during 
planned bariatric surgery is sent for histopathology in 
some cases and is typically unremarkable.[13] In this 
case, there were multiple risk factors ,including H.pylori 
infection, which was treated, hiatal hernia, persistent 
GERD, and obesity. There was an interval between the 
two EGDs done after the surgery, which could give rise 
to further degeneration. Another interesting aspect is 
to consider sending the resected stomach during sleeve 
gastrectomy for histopathology in such patients, as they 
are considered high risk.[14] It is worth pointing out 
that post-operative EGD might be necessary in high-risk 
patients, and it should be done annually after to detect 
any dysplasia or masses.[15]
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